Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Invested Capital (2016 - 2026)

Gyre Therapeutics has reported Invested Capital over the past 16 years, most recently at $142.3 million for Q4 2025.

  • Quarterly Invested Capital rose 124.71% to $142.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $142.3 million through Dec 2025, up 124.71% year-over-year, with the annual reading at $142.3 million for FY2025, 124.71% up from the prior year.
  • Invested Capital was $142.3 million for Q4 2025 at Gyre Therapeutics, up from $101.9 million in the prior quarter.
  • Over five years, Invested Capital peaked at $142.3 million in Q4 2025 and troughed at $13.9 million in Q4 2023.
  • The 5-year median for Invested Capital is $82.1 million (2021), against an average of $79.7 million.
  • Year-over-year, Invested Capital plummeted 80.68% in 2023 and then surged 353.93% in 2024.
  • A 5-year view of Invested Capital shows it stood at $59.5 million in 2021, then increased by 21.44% to $72.2 million in 2022, then plummeted by 80.68% to $13.9 million in 2023, then surged by 353.93% to $63.3 million in 2024, then surged by 124.71% to $142.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Invested Capital are $142.3 million (Q4 2025), $101.9 million (Q3 2025), and $129.4 million (Q2 2025).